Tirzepatide: Safety Profile & Research Summary
8 PubMed CitationsExpert ReviewedGMP CertifiedLast Reviewed: July 2026
Research Summary
Foundational Studies
| Study | Model | Key Findings | Ref |
|---|---|---|---|
| Coskun et al. (2018) | Cell/rodent + phase 1 | First unimolecular dual GIP/GLP-1 receptor agonist; discovery-to-proof-of-concept characterization | [1] |
| Willard et al. (2020) | Recombinant receptor assays | Characterized tirzepatide as an imbalanced/biased dual agonist (GIP-like at GIPR; biased at GLP-1R) | [4] |
| Rosenstock et al. (2021) | SURPASS-1 (T2D) | Dose-dependent reductions in HbA1c and body weight vs placebo | [6] |
| Frias et al. (2021) | SURPASS-2 (T2D) | Greater HbA1c and body-weight reduction vs semaglutide 1 mg | [5] |
| Jastreboff et al. (2022) | SURMOUNT-1 (obesity) | Substantial dose-dependent body-weight reduction in adults with obesity | [3] |
| Samms et al. (2020) | Review / preclinical | Mechanistic framework for how GIP-receptor agonism may enhance GLP-1 efficacy | [7] |
Mechanistic Themes
- Dual incretin agonism - a single peptide engages both the GIP and GLP-1 receptors
- Imbalanced/biased signaling - GIP-like at GIPR, biased (cAMP-favoring) at GLP-1R
- Extended pharmacokinetics - Aib substitutions plus C20 fatty-diacid albumin binding support ~5-day half-life
- Glucose-dependent action - insulinotropic effect is conditioned on ambient glucose
In Vitro / Preclinical Disclaimer: The research findings described above were observed in laboratory (in vitro), animal model, and clinical research studies of the pharmaceutical product. Research-grade material sold here is for laboratory research use only. No claims are made regarding human therapeutic use of this research-grade product.
Educational Use Only: This content is provided for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult qualified healthcare professionals for medical decisions.
Expert Observation
“(2018)Cell/rodent + phase 1First unimolecular dual GIP/GLP-1 receptor agonist; discovery-to-proof-of-concept characterization[1] Willard et al.”
References
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143-157.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515.
- Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155.
- Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421.
- Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19(4):201-216.
Related Research Questions
Want the complete research review?
View Full Tirzepatide Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.